Ultimately however, the immune system is confronted with persistent exposure to tumorantigens, frequently in a non-inflammatory context, favoring the establishment of tolerance 2 . Much like tolerance to normal self-antigens, tolerance to tumor-associated antigens may arise from a failure to encounter antigen (ignorance) or the deletion or functional inactivation (anergy) of tumor-specific T cells.
There is a growing body of evidence that dominant forms of tolerance such as T cell suppression play a particularly important role in preventing reactivity to selfantigens [3] [4] [5] . The cells that have been implicated as regulatory T cells (Tregs) differ greatly in terms of their origin, differentiation, phenotype and mode of action. The so-called "natural" CD4 + CD25 + Tregs are thought to arise as a distinct lineage from the thymus 6, 7 .
But regulatory function can also be acquired by uncommitted, CD4 + T cells under particular conditions of antigenic stimulation. These so-called "induced" Tregs are likewise heterogeneous, including IL10-producing type-1 T regulatory (Tr1) cells 8, 9 and TGF -producing Th3 cells 10 .
While much of the initial attention focused on the role of Tregs in controlling selfreactivity, there is growing evidence that Tregs significantly impact on the host response For personal use only. on October 23, 2017. by guest www.bloodjournal.org From to cancer 11, 12 . In several models, tumor immunosurveillance is augmented when CD4 + CD25 + Tregs are depleted [13] [14] [15] [16] . Removing CD4 + CD25 + Tregs has also been shown to enhance tumor immunity elicited by vaccination 17 . In humans, CD4 + CD25 + T cells have been identified at increased frequency in the peripheral blood and malignant effusions of patients with several types of cancers [18] [19] [20] . Although the specificities of these populations are largely unknown, a recent study reported isolating CD4 
Antibodies and flow cytometry
Antibodies for flow cytometry were anti-CD4 (APC, PerCP and Cyc), Thy1.1 (PerCP and PE), Thy1.2-APC, CD25 (APC and PE), CD62LPE, CTLA-4-PE and GITR-PE (R&D Systems, Minneapolis, MN). All antibodies were purchased from BD Biosciences (Mountain View, CA) unless otherwise specified. All FACS analysis was of surface expression except for CTLA-4 and FoxP3, for which cells were permeablized. 30,000 gated events were collected on a FACSCalibur (Becton Dickinson, San Jose, California) and analyzed using CellQuest software (Becton Dickinson, San Jose, California).
Tumor cells and adoptive transfer
The generation and maintenance of A20HA B cell lymphoma cells was described previously 44 . 1×10 6 tumor cells were injected via tail vein. For adoptive transfer using 45 .
Cell sorting and quantitative real-time PCR analysis

CD4
+ enriched cells were stained with anti-Thy1.1 in combination with specified mAbs, and were sorted on FACSAria (Becton Dickinson). Cells were gated on Thy1.1-positive population and sorted into CFSE high (undivided) and CFSE low (O2 cycles) subpopulations.
The purity of the sorted cells was typically >97%.
RNA was extracted using RNAeasy Kit (QIAGEN) and was DnaseI treated. cDNA was synthesized using the SuperScript First-Strand Synthesis System (Invitrogen, Carlsbad, CA). cDNA amounts were analyzed by real-time quantitative PCR (qRT-PCR) with the Taqman system (Applied Biosystems, Foster City, CA). Each sample was assayed in triplicate for target gene with the internal reference, HPRT, using the Taqman Universal PCR Master Mix and the ABI Prism 7700 Sequence Detection System (Applied Biosystems). Primers and probes for FoxP3 were previously reported 26 . IFNR, IL2, IL10, IL4, TGFI and HPRT were purchased as PDARs from Applied Biosystems. The relative 
Monitoring for Diabetes
Mice were followed for the development of diabetes by monitoring tail blood glucose levels at the indicated time points using a MediSense Precision Q.I.D glucometer 
Statistical Analysis
The significance of the results was determined using the Student's t-test. P<0.05 was considered statistically significance. In contrast, when the divided HA specific T cells from vacHA primed, tumor-bearing mice were separated based on GITR expression, the GITR low subset was competent in TMTregs in an analogous fashion, tumor-specific T cell anergy also develops in response to antigen expressed by renal cell carcinoma, melanoma, and breast cancer 29, 33 , and chimera studies show that even in the case of lymphoma, antigen presentation by bone marrow-derived APCs (not the lymphoma itself) is required for tumor-specific anergy 25 .
Whereas the phenotypic subsets of TMTregs may arise from different developmental pathways, our data demonstrate that at least some GITR high TMTregs can be induced In line with these reports, we found that TMTregs were unable to upregulate CD40L upon rechallenge, though primary CD8 response to vacHA was not affected in the presence of TMTregs (data not shown), implying that TMTregs may largely influence the effector/memory phase of CTLs.
Since the resurrection of T cell suppression as a legitimate area of inquiry and the growing appreciation of the role it plays in maintaining tolerance to self antigens, it has become clear that regulatory function can be attributed to cells with diverse phenotypes, origins, and modes of action. Indeed, the in vivo system examined here provides an opportunity to identify factors that influence Treg induction as well as how discrete phases of an effector response may be differentially regulated. However, regardless of the mechanisms contributing to the induction and function of such cells, a major insight from these studies is that measurements made of tumor-specific immune responses reflect the integrated sum of effector cells and regulatory T cells, both of which may be amplified by therapeutic vaccination. Of obvious clinical relevance, the demonstration that tumor induced regulatory T cells can be expanded by immunization underscores the potential 
